ArticleThe Lancet regional health. Western Pacific2022
Seroprevalence of Hepatitis B, C and D in Vietnam: A systematic review and meta-analysis.
Article in The Lancet regional health. Western Pacific, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- The Dual Burden of Hepatitis B and C Among Drug Users in Asia: The First Systematic Review and Meta-Analysis.Pathogens (Basel, Switzerland) · 2025Pooled it
- Seroprevalence of viral hepatitis B and C infections among healthcare workers in Ethiopia: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Risk of Hepatitis B Reactivation Following Corticosteroids for Tuberculous Meningitis.Open forum infectious diseases · 2026Article
- Clinical Outcomes of Breast-Involved Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Real-World Study with Insights into CNS Prophylaxis.Current oncology (Toronto, Ont.) · 2026Article
- High Burden of Occult Hepatitis B Infection in HIV-Infected Patients in Southern Vietnam: Insights from Serological and Molecular Analysis.International journal of molecular sciences · 2026Article
- Unravelling HCV diversity and resistance in Viet Nam: a cross-sectional analysis.The Lancet regional health. Western Pacific · 2026Article
- Unveiling the Hidden Reservoir: High Prevalence of Occult Hepatitis B and Associated Surface Gene Mutations in a Healthy Vietnamese Adult Cohort.Microorganisms · 2026Article
- Population immunity to hepatitis B virus and infection marker seroprevalence in Belgrade, Serbia.Frontiers in public health · 2026Article
- Unexpectedly low prevalence of hepatitis delta virus infection in Southern Viet Nam.Scientific reports · 2025Article
- First identification of occult hepatitis B infection among ethnic minority students in Thai Nguyen, Vietnam.BMC infectious diseases · 2025Article
- Genomic surveillance of HBV and HDV reveals genotype-specific risk of liver disease in central Vietnam.Scientific reports · 2025Article
- Unexpectedly Low Prevalence of Hepatitis Delta Virus Infection in Southern Viet Nam.Research square · 2025Article
- Hepatitis C virus incidence trend and its risk factors among people who inject drugs in Hai Phong, Vietnam.Hepatology international · 2025Article
- Parenteral viral hepatitis among students in Da Nang, Vietnam, and insights into new hepatitis B virus genotype B classification.Scientific reports · 2025Article
- High Seroprevalence of Hepatitis E Virus Among Patients With Hepatitis B and Those With Hepatitis of Unknown Etiology in Central Vietnam.Open forum infectious diseases · 2025Article
- Success Metrics for Hepatitis C Elimination Among People Who Inject Drugs: A Scoping Review of Indicators in Harm Reduction.International journal of environmental research and public health · 2025Article
- Genetic intersection of human leukocyte antigen-DP/DQ and hepatitis B virus-related liver disease: Insights from a multi-clustering study.World journal of gastroenterology · 2025Article
- Putting people at the center: methods for patient journey mapping of viral hepatitis services across two LMICs in the Asia Pacific.BMC health services research · 2025Article
- Prospective validation study: a non-invasive circulating tumor DNA-based assay for simultaneous early detection of multiple cancers in asymptomatic adults.BMC medicine · 2025Observational
- Economic evaluation of tenofovir disoproxil fumarate prophylaxis to prevent mother-to-child transmission of Hepatitis B virus infection: evidence from a lower-middle income country.BMC health services research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Background: Vietnam has one of the greatest disease burdens from chronic viral hepatitis. Comprehensive prevalence data are essential to support its elimination as a public health threat. Methods: We searched Medline and Embase from 1990 to 2021 for seroprevalence data relating to Hepatitis B (HBV), C (HCV) and D (HDV) in Vietnam. We estimated pooled prevalence with a DerSimonian-Laird random-effects model and stratified study populations into i) low-risk ii) high-risk exposure and iii) liver disease. We further estimated prevalence by decade and region and rates of HIV-coinfection. Findings: We analysed 72 studies, including 120 HBV, 114 HCV and 23 HDV study populations. Pooled HBV prevalence was low in blood donors (1.86% [1.82-1.90]) but high in antenatal populations (10.8% [10.1-11.6]) and adults in the general population (10.5% [10.0-11.0]). It was similar or modestly increased in groups at highest risk of exposure, suggesting the epidemic is largely driven by chronic infections acquired in childhood. HCV pooled prevalence in the general population was lower than historical estimates: 0.26% (0.09-0.51) have active infection defined by detectable antigen or HCV RNA. In contrast, there is an extremely high prevalence of active HCV infection in people who inject drugs (PWID) (57.8% [56.5-59.1]), which has persisted through the decades despite harm-reduction interventions. HDV appears mainly confined to high-risk groups. Interpretation: Blood safety has improved, but renewed focus on HBV vaccination at birth and targeted HCV screening and treatment of PWID are urgently required to meet elimination targets. Large cross-sectional studies are needed to better characterize HDV prevalence, but mass screening may not be warranted. Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.